Hanus M, Lafon J, Mathieu M · Curr Med Res Opin (2004)
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
4 peer-reviewed studies
What the evidence says
Most California Poppy studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2001–2016.
Based on 4 studies · 1 RCT
Confidence
Low confidenceBy outcome
Newest study from 2016
Hanus M, Lafon J, Mathieu M · Curr Med Res Opin (2004)
In plain English: Ethanolic California poppy extract and its alkaloids inhibited several CYP enzymes and activated PXR in vitro, signalling herb-drug interaction potential, whereas the aqueous tea appeared safer.
Manda VK, Ibrahim MA, Dale OR, et al. · Planta Med (2016)
In plain English: California poppy alkaloid (S)-reticuline acted as a positive allosteric modulator at several GABA-A receptor isoforms, providing a molecular basis for the herb's depressant effects.
Fedurco M, Gregorová J, Šebrlová K, et al. · Biochem Res Int (2015)
In plain English: The sedative and anxiolytic effects of California poppy extract in mice were suppressed by the benzodiazepine antagonist flumazenil, pointing to benzodiazepine-receptor involvement.
Rolland A, Fleurentin J, Lanhers MC, Misslin R, Mortier F. · Phytother Res (2001)